Brown Gibbons Lang & Company (BGL) announced today the sale of Orthoproducts Limited and its wholly-owned subsidiary Orthoplastics Limited (Orthoplastics) to MedPlast, Inc. (MedPlast). BGL’s Healthcare & Life Sciences team and Industrials team jointly initiated the transaction and served as the exclusive financial advisor to Orthoplastics. The specific terms of the transaction were not disclosed.
Orthoplastics is a leading manufacturer of ultra-high molecular weight polyethylene (UHMWPE) products and components for the global orthopedic implant market. UHMWPE is the leading material technology used for acetabular cup linings in hip implant systems, and patella inserts and articulating surfaces in knee implant systems. As one of the major UHMWPE product suppliers to the strictly regulated orthopedic implant market, Orthoplastics’ products may be found in nearly half of the world’s hip and knee implants. The company’s advanced engineering and production capabilities have positioned it as a vital link in the global supply chain for next generation orthopedic devices. Orthoplastics is based in Bacup, UK, and was a portfolio company of Harwood Private Equity and other funds managed by Harwood Capital LLP. For more information on Orthoplastics, please visit www.orthoplastics.com.
MedPlast is a leading provider of highly engineered custom plastic processing solutions serving the global healthcare market. The company applies its materials expertise in thermoplastics and elastomers to develop processing solutions for medical components and devices. The company operates through eleven manufacturing facilities in the US, UK, China, and Mexico. This acquisition expands MedPlast’s ability to serve the orthopedic device OEMs, while significantly growing its customer base and global strategic footprint. The company is based in Tempe, Arizona, and is a portfolio company of Baird Capital. For more information on MedPlast, please visit www.medplastgroup.com.
John Riddle and Andrew Petryk led the BGL transaction team.